Browse by author
Lookup NU author(s): Professor Ruth Plummer
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Poly(ADP-ribose) polymerase (PARP) inhibitors are a novel class of anticancer agents that target the DNA damage response pathways. The enzyme target, PARP, plays a key role in signalling DNA single-strand breaks. Clinical development to date has focused on their potential role in combination with DNA-damaging chemotherapy, where efficacy has been limited by enhanced normal tissue toxicity, and as single agents in the context of synthetic lethality. This article reviews these data in the context of future development as radio-potentiating agents. (C) 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Author(s): Plummer R
Publication type: Article
Publication status: Published
Journal: Clinical Oncology
Print publication date: 01/05/2014
Online publication date: 04/03/2014
Acceptance date: 11/02/2014
ISSN (print): 0936-6555
ISSN (electronic): 1433-2981
Publisher: W.B. Saunders Co. Ltd
Altmetrics provided by Altmetric